Pharmaceuticals

Dopamine Agonists Industry Insights: Market Forecast to 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Dopamine Agonists Market Size Likely To Evolve From 2025 Through 2034?

The market size for dopamine agonists has experienced substantial growth in recent years. It is anticipated to increase from $2.57 billion in 2024 to $2.73 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.4%. This historical growth can be linked to several factors, including the rising incidence of Parkinson’s disease, an increase in the diagnosis of restless legs syndrome (RLS), broader reimbursement coverage, enhanced funding for CNS disorder research, and greater healthcare awareness.

The dopamine agonists market is anticipated to experience substantial expansion over the coming years, with projections indicating it will reach $3.61 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period can be attributed to factors such as the increasing prevalence of neurological disorders, an aging global population, a rise in research and clinical trials, the expansion of combination therapies, and enhanced awareness and diagnosis rates. Significant trends for this period include personalized medicine and genetic profiling, the development of wearable drug delivery systems, the integration of artificial intelligence and machine learning in drug development, the introduction of extended-release formulations, and advancements in nanotechnology for drug delivery.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23375&type=smp

Which Industry Drivers Are Expected To Accelerate The Dopamine Agonists Market From 2025 To 2029?

The increasing occurrence of neurological disorders is anticipated to stimulate the expansion of the dopamine agonist market. Neurological disorders are health issues that impact the brain, spine, or nerves, leading to difficulties with movement, thought processes, or behavior. The growing prevalence of these disorders is partly attributable to extended life expectancies, as the risk of conditions such as Alzheimer’s and Parkinson’s increases with age. Dopamine agonists are instrumental in treating neurological disorders like Parkinson’s disease by activating dopamine receptors in the brain, which improves control and lessens symptoms. For instance, according to the 2024 Alzheimer’s Disease Facts and Figures report by the Alzheimer’s Association, a US-based nonprofit voluntary health organization focused on Alzheimer’s disease care, support, and research, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer’s dementia in 2022, a number projected to increase to 6.9 million in 2024. Thus, the escalating prevalence of neurological disorders will be a key driver for the dopamine agonist market’s growth.

What Are The Major Segments Identified In The Dopamine Agonists Market?

The dopamine agonists market covered in this report is segmented –

1) By Product Type: Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists

2) By Route of Administration: Oral, Parenteral, Transdermal Patches

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

4) By Application: Parkinson’s Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia

5) By End User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) Ergot-Based Dopamine Agonists: Bromocriptine, Cabergoline, Pergolide

2) Non-Ergot-Based Dopamine Agonists: Pramipexole, Ropinirole, Rotigotine, Apomorphine

Which Competitive Trends Are Defining The Dopamine Agonists Market Structure?

Leading companies in the dopamine agonists market are concentrating on innovations such as flexible-dose monotherapy, aiming to enhance patient adherence, reduce side effects, and provide more personalized treatment options for neurological disorders. This treatment approach involves a single drug with adjustable dosing, allowing medical professionals to tailor the amount to each patient’s specific needs and response. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, announced positive topline results from its Phase 3 TEMPO-2 trial. This study demonstrated that investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), significantly improved motor function in early Parkinson’s disease patients. The trial successfully met its primary endpoint with a notable reduction in MDS-UPDRS Parts II and III scores and also achieved key secondary endpoints, showing meaningful improvement in daily motor activities. Tavapadon is the first D1/D5 partial agonist currently under investigation for once-daily Parkinson’s treatment.

Which Major Industry Participants Are Leading The Dopamine Agonists Market Growth?

Major companies operating in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/dopamine-agonists-global-market-report

How Do Regional Market Performances Compare Within The Dopamine Agonists Industry?

North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dopamine agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Dopamine Agonists Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23375&type=smp

Browse Through More Reports Similar to the Global Dopamine Agonists Market 2025, By The Business Research Company

Nerve Repair And Regenerative Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Optic Nerve Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optic-nerve-disorders-treatment-global-market-report

Central Nervous System Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795